Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 5/20 | 0.62 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KLK7 | P49862 | 1/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4224747 | 1.00 | PREP (0.62) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL11262909 | 0.91 | PREP (0.69) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL11262912 | 0.91 | PREP (0.69) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL488745 | 0.89 | PREP (0.68) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL488744 | 0.89 | PREP (0.68) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL8750854 | 0.89 | PREP (0.68) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL8750947 | 0.89 | PREP (0.68) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL6384850 | 0.89 | PREP (0.68) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL8750859 | 0.89 | PREP (0.68) | PREPCTRB1NPSR1TSHRL3MBTL1 | |
| SCHEMBL8161155 | 0.88 | PREP (0.67) | PREPCTRB1NPSR1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| EP-1861412-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | PREP 4682/4885CTRB1 1594/4885NPSR1 141/4885 |
| US-20090240045-A1 | Organic Compounds | CYP3A43, CYP3A4, SLCO1B3 | PREP 3082/4885CTRB1 1167/4885NPSR1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.